BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27272709)

  • 21. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
    Lansing TJ; Turk BF; Kanner SB; Gilmer TM
    Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Down-regulated expression of PP2A catalytic subunit in pancreatic cancer cells promotes cell growth].
    Li W; Gong F; Chen Z; Zong Y; Chen K; Li D; Tao M; Xu Z
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):86-9. PubMed ID: 24721345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation.
    Kim MJ; Byun JY; Yun CH; Park IC; Lee KH; Lee SJ
    Mol Cancer Res; 2008 Dec; 6(12):1872-80. PubMed ID: 19074832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
    Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
    Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist.
    Sun X; Cui M; Zhang A; Tong L; Wang K; Li K; Wang X; Sun Z; Zhang H
    J Exp Clin Cancer Res; 2016 Jan; 35():10. PubMed ID: 26762267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42.
    Levi NL; Hanoch T; Benard O; Rozenblat M; Harris D; Reiss N; Naor Z; Seger R
    Mol Endocrinol; 1998 Jun; 12(6):815-24. PubMed ID: 9626657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus‑mediated overexpression of cystic fibrosis transmembrane conductance regulator enhances invasiveness and motility of serous ovarian cancer cells.
    Xu J; Lin L; Yong M; Dong X; Yu T; Hu L
    Mol Med Rep; 2016 Jan; 13(1):265-72. PubMed ID: 26549617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Astrocyte elevated gene-1 (AEG-1) promotes osteosarcoma cell invasion through the JNK/c-Jun/MMP-2 pathway.
    Wang F; Ke ZF; Wang R; Wang YF; Huang LL; Wang LT
    Biochem Biophys Res Commun; 2014 Oct; 452(4):933-9. PubMed ID: 25204501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of PPP2R1A mutations in Wilms tumor.
    Ruteshouser EC; Ashworth LK; Huff V
    Oncogene; 2001 Apr; 20(16):2050-4. PubMed ID: 11360189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective involvement of p130Cas/Crk/Pyk2/c-Src in endothelin-1-induced JNK activation.
    Kodama H; Fukuda K; Takahashi E; Tahara S; Tomita Y; Ieda M; Kimura K; Owada KM; Vuori K; Ogawa S
    Hypertension; 2003 Jun; 41(6):1372-9. PubMed ID: 12719447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability.
    Houge G; Haesen D; Vissers LE; Mehta S; Parker MJ; Wright M; Vogt J; McKee S; Tolmie JL; Cordeiro N; Kleefstra T; Willemsen MH; Reijnders MR; Berland S; Hayman E; Lahat E; Brilstra EH; van Gassen KL; Zonneveld-Huijssoon E; de Bie CI; Hoischen A; Eichler EE; Holdhus R; Steen VM; Døskeland SO; Hurles ME; FitzPatrick DR; Janssens V
    J Clin Invest; 2015 Aug; 125(8):3051-62. PubMed ID: 26168268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analysis in endometrial cancer.
    Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
    Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential.
    Irby R; Mao W; Coppola D; Jove R; Gamero A; Cuthbertson D; Fujita DJ; Yeatman TJ
    Cell Growth Differ; 1997 Dec; 8(12):1287-95. PubMed ID: 9419417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-Jun controls the efficiency of MAP kinase signaling by transcriptional repression of MAP kinase phosphatases.
    Sprowles A; Robinson D; Wu YM; Kung HJ; Wisdom R
    Exp Cell Res; 2005 Aug; 308(2):459-68. PubMed ID: 15950217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reconstitution of signal transduction from the membrane to the nucleus in a baculovirus expression system: activation of Raf-1 leads to hypermodification of c-jun and c-fos via multiple pathways.
    Agarwal S; Corbley MJ; Roberts TM
    Oncogene; 1995 Aug; 11(3):427-38. PubMed ID: 7543194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.